Pfizer Aktie
WKN: 852009 / ISIN: US7170811035
|
29.05.2015 04:44:30
|
Cellectis In Sale Talks With Pfizer : Report
(RTTNews) - The French biotech company Cellectis (CLLS) is in talks about its potential sale with Pfizer (PFE) of the US believed to be among the buyers, the Financial Times reported citing people familiar with matter.
The report indicated Cellectis was in negotiations over a deal but warned that no outcome was certain. One person said Pfizer had informally approached the company about a deal that could value the target at as much as 1.5 billion euros.
It is unclear if other parties were also in the sale talks with Cellectis, the report said.
CLLS closed Thursday's regular trading at $47.66, up $6.67 or 16.27%. In after-hours, the share further gained $0.29 or 0.61%.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Cellectis SA (spons. ADRs)mehr Nachrichten
|
11.05.25 |
Ausblick: Cellectis präsentiert Quartalsergebnisse (finanzen.net) | |
|
12.03.25 |
Ausblick: Cellectis stellt Zahlen zum jüngsten Quartal vor (finanzen.net) |
Analysen zu Pfizer Inc.mehr Analysen
| 21.05.25 | Pfizer Buy | Jefferies & Company Inc. | |
| 29.04.25 | Pfizer Buy | Jefferies & Company Inc. | |
| 29.04.25 | Pfizer Neutral | JP Morgan Chase & Co. | |
| 29.04.25 | Pfizer Neutral | UBS AG | |
| 14.04.25 | Pfizer Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
| Cellectis SA (spons. ADRs) | 1,26 | 1,61% |
|
| Pfizer Inc. | 20,40 | -0,12% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.